All In Biotech

Drug Trial Radar · NCT07903623

QLS4131 Plus Isatuximab in Newly Diagnosed Primary Plasma Cell Leukemia

A Prospective, Single-Arm, Single-Center Clinical Study of QLS4131 Combined With Isatuximab in Patients With Newly Diagnosed Primary Plasma Cell Leukemia

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Oct 25, 2026

Primary completion

Dec 30, 2029

Study completion Dec 30, 2031

Sponsor

Lead sponsor
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn whether QLS4131, a BCMA/GPRC5D/CD3 trispecific antibody, can improve treatment outcomes when combined with isatuximab in adults with newly diagnosed primary plasma cell leukemia (pPCL). The study will also evaluate the safety of this treatment combination. The main questions it aims to answer are: * How many participants achieve measurable residual disease (MRD) negativity after 9 treatment cycles? * What side effects occur during treatment with QLS4131 combined with isatuximab? * How many participants respond to treatment, and how many achieve a complete response? * How many participants achieve sustained MRD negativity? * How long do participants remain free from disease progression, and how long do they survive after starting treatment? All participants will receive the study treatment. There is no comparison group in this study. Participants will: * Receive QLS4131 by subcutaneous injection together with intravenous isatuximab in 28-day treatment cycles. * Undergo regular blood tests, bone marrow examinations, and disease assessments to monitor treatment response and safety. * Undergo peripheral blood stem cell mobilization and collection after the first 3 treatment cycles, if appropriate. * Be monitored throughout the study for side effects, including adverse events and serious adverse events.

Conditions

  • Primary Plasma Cell Leukemia

Interventions

  • QLS4131Drug

    QLS4131 is administered subcutaneously (SC) using a step-up dosing regimen, followed by a target dose of 12 mg. During Cycle 1, QLS4131 is administered every 2 weeks; from Cycle 2 through Cycle 18, it is administered every 4 weeks.

  • IsatuximabDrug

    Isatuximab is administered intravenously (IV) at 10 mg/kg. It is given weekly during Cycle 1, every 2 weeks during Cycles 2-12, and every 4 weeks during Cycles 13-18.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Minimal residual disease (MRD) negative rateTime frame: After 9 cycles (each cycle is 28 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.